Matthias Preusser

Matthias Preusser (born 29 October 1976, Mödling) is an Austrian oncologist and Professor of Medical Oncology as well as Head of the Clinical Division of Oncology at the Medical University of Vienna. He is known for his work on neurooncology, Molecular Therapy targets and biomarkers and immunotherapy of cancer.

Matthias Preusser
Born (1976-10-29) 29 October 1976
Mödling
NationalityAustrian
Known forneurooncology, Molecular medicine targets, biomarkers.
AwardsCardinal-Innitzer-Price (2009), Sibylle Assmus Price for Neuro-Oncology (2009), Advancement award of the city of Vienna (2010, 2013)
Scientific career
Fieldsinternal medicine, hematology, medical oncology
InstitutionsMedical University of Vienna

Biography

Preusser studied medicine at the Medical University of Vienna, received his Medical Doctor (M.D.) degree in 2003 and holds specialist diplomas for internal medicine, hematology and medical oncology. He achieved habilitation in the field of Experimental Oncology 2009 with the thesis Analysis of Biomarkers in Brain Tumours and in the field of Internal Medicine 2016 with the thesis Personalized Therapy of Cancer. From 2009 he spent stays abroad at the German Cancer Research Center, Heidelberg and at the Memorial Sloan-Kettering Cancer Center, New York. On October 1st 2018 Preusser was appointed as full Professor of Medical Oncology and on November 1st 2018 as Head of the Clinical Division of Oncology at the Medical University of Vienna. He also serves as coordinator of the brain tumor unit of the Comprehensive Cancer Center – Central Nervous System (CCC-CNS).

Scientific contributions

Preusser's scientific work deals with the identification of molecular changes with prognostic and therapeutic relevance in brain tumors. His investigations on the significance of the MGMT gene[1] (O-6-methylguanine-DNA methyltransferase), the IDH gene[2] (glioblastoma multiforme) and the BRAF gene[3] and the immunophenotype inlcuing the role of PD-L1 in gliomas and brain metastases are highly cited and he is co-author of the current WHO brain tumor classification, which is considered an international standard reference.[4] The oncologist leads several international clinical studies including a randomised therapy trial on high grade meningioma.

Academic memberships
  • European Society of Medical Oncology ESMO
  • European Organisation for Research and Treatment of Cancer (EORTC)
  • European Association of Neurooncology (EANO)
  • Society of Austrian Neurooncology (SANO) (cofounder and first secretary)
  • Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie (ÖGHO)
  • Central European Cooperative Oncology Group (CECOG)

Honors and awards
  • 2008 Medical University of Vienna Researcher of the month
  • 2009 Cardinal-Innitzer-Price (advancement award)[5]
  • 2009 Sibylle Assmus Price for Neuro-Oncology, Heidelberg[6]
  • 2011 EANO Fellowship Grant[7]
  • 2010 und 2013 Advancement award of the city of Vienna[8]

Publications

Publication list PubMed

gollark: The build number doesn't look like either of those.
gollark: ???
gollark: The whole process is in my opinion pretty stupid.
gollark: You overwrite the system image with different stuff.
gollark: https://forum.xda-developers.com/galaxy-tab-e/development/unofficial-lineageos-14-1-galaxy-tab-e-t3903780I don't particularly trust it.

References
  1. M. Preusser, Charles R. Janzer, J. Felsberg, G. Reifenberger, M. F. Hamou, A. C. Diserens, R. Stupp, T. Gorlia, C. Marosi, H. Heinzl, J. A. Hainfellner, M. Hegi: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008 Oct;18(4), S. 520–532. doi:10.1111/j.1750-3639.2008.00153.x.
  2. M. Preusser, A. Wöhrer, S. Stary, R. Höftberger, B. Streubel, J. A. Hainfellner: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011 Aug;70(8), S. 715–723. doi:10.1097/NEN.0b013e31822713f0.
  3. D. Capper, A. S. Berghoff, M. Magerle, A. Ilhan, A. Wöhrer, M. Hackl, J. Pichler, S. Pusch, J. Meyer, A. Habel, P. Petzelbauer, P. Birner, A. von Deimling, M. Preusser: Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012 Feb;123(2), S. 223–233. doi:10.1007/s00401-011-0887-y.
  4. WHO brain tumor classification
  5. onkologie-wien.at
  6. stiftung-sibylle-assmus.de Archived 7 December 2013 at the Wayback Machine
  7. docstoc.com
  8. meduniwien.ac.at
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.